Translational Research Working Group developmental pathway for immune response modifiers.
The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.
Cheever
Martin A
MA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Schlom
Jeffrey
J
Weiner
Louis M
LM
Lyerly
H Kim
HK
Disis
Mary L
ML
Greenwood
Addison
A
Grad
Oren
O
Nelson
William G
WG
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000628:therapy*; D009934:Organization and Administration; D016730:Program Development; D012985:Software Design; D014481:United States
D019496:Cancer Vaccines; D007155:Immunologic Factors
J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601
9362157
Blood. 1994 Oct 1;84(7):2221-8
7919339
J Clin Oncol. 1997 Nov;15(11):3363-7
9363867
Crit Rev Immunol. 2007;27(5):451-62
18197807
N Engl J Med. 2008 Jun 19;358(25):2704-15
18565863
Clin Cancer Res. 1999 Jun;5(6):1289-97
10389911
Clin Cancer Res. 2005 Jun 15;11(12):4430-6
15958627
Biol Blood Marrow Transplant. 2005 Jan;11(1):23-34
15625541
Adv Immunol. 2006;90:297-339
16730267
Exp Biol Med (Maywood). 2008 May;233(5):522-34
18375829
Clin Cancer Res. 2008 Sep 15;14(18):5664-71
18612047
Nat Rev Cancer. 2005 May;5(5):397-405
15864281
J Immunol. 1996 May 1;156(9):3151-8
8617935
Immunol Rev. 2008 Apr;222:357-68
18364014
Update Cancer Ther. 2007 Mar;2(1):33-39
17948067
Cancer Res. 1969 Apr;29(4):848-54
4887203
J Clin Oncol. 2004 May 15;22(10):1916-25
15143085
J Clin Oncol. 2002 Jun 1;20(11):2624-32
12039923
Cancer Res. 1981 Apr;41(4):1358-62
7011535